Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates

With an upside potential of 21.26% as of May 3, Merck & Co., Inc. (NYSE:MRK) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts.

Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates

Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products.

On May 1, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $109 to $112, while maintaining an ‘Equal Weight’ rating on the shares.

The target boost comes after Merck & Co., Inc. (NYSE:MRK) beat topline estimates in its Q1 results posted on April 30, driven by the strong demand for its aging cancer immunotherapy Keytruda. Sales of the medicine rose 12% to $8 billion during the quarter, beating expectations of $7.6 billion.

Merck & Co., Inc. (NYSE:MRK) also narrowed its ​previous guidance range, pushing up ​the midpoint of both its full-year revenue and EPS guidance. The ⁠company now expects a 2026 profit of $5.04 to $5.16 per share on sales of $65.8 billion to $67 billion, compared with a previous estimate of $5.00 to $5.15 ​per share on sales of $65.5 billion to $67 billion.

According to Morgan Stanley, pipeline execution and capital deployment are the two key factors for MRK.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Blue Chip Stocks to Invest In According to Billionaires and 10 Best Fortune 500 Dividend Stocks to Invest In Right Now

Disclosure: None. Follow Insider Monkey on Google News.